Society of gynecologic oncology statement on risk assessment for inherited gynecologic cancer predispositions

SGO Clinical Practice Committee

Research output: Contribution to journalArticle

116 Citations (Scopus)

Abstract

Women with germline mutations in the cancer susceptibility genes, BRCA1 or BRCA2, associated with Hereditary Breast & Ovarian Cancer syndrome, have up to an 85% lifetime risk of breast cancer and up to a 46% lifetime risk of ovarian, tubal, and peritoneal cancers. Similarly, women with mutations in the DNA mismatch repair genes, MLH1, MSH2, MSH6, or PMS2, associated with the Lynch/Hereditary Non-Polyposis Colorectal Cancer (HNPCC) syndrome, have up to a 40-60% lifetime risk of both endometrial and colorectal cancers as well as a 9-12% lifetime risk of ovarian cancer. Mutations in other genes including TP53, PTEN, and STK11 are responsible for hereditary syndromes associated with gynecologic, breast, and other cancers. Evaluation of the likelihood of a patient having one of these gynecologic cancer predisposition syndromes enables physicians to provide individualized assessments of cancer risk, as well as the opportunity to provide tailored screening and prevention strategies such as surveillance, chemoprevention, and prophylactic surgery that may reduce the morbidity and mortality associated with these syndromes. Evaluation for the presence of a hereditary cancer syndrome is a process that includes assessment of clinical and tumor characteristics, education and counseling conducted by a provider with expertise in cancer genetics, and may include genetic testing after appropriate consent is obtained. This commentary provides guidance on identification of patients who may benefit from assessment for the presence of a hereditary breast and/or gynecologic cancer syndrome.

Original languageEnglish (US)
Pages (from-to)3-7
Number of pages5
JournalGynecologic Oncology
Volume136
Issue number1
DOIs
StatePublished - 2015

Fingerprint

Neoplasms
Ovarian Neoplasms
Colorectal Neoplasms
Breast
Hereditary Neoplastic Syndromes
Breast Neoplasms
Mutation
DNA Mismatch Repair
Process Assessment (Health Care)
Germ-Line Mutation
Neoplasm Genes
p53 Genes
Chemoprevention
Genetic Testing
Endometrial Neoplasms
Counseling
Morbidity
Physicians
Education
Mortality

Keywords

  • BRCA1
  • BRCA2
  • Cowden syndrome
  • Genetic testing
  • Hereditary cancer
  • Lynch syndrome

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology
  • Medicine(all)

Cite this

Society of gynecologic oncology statement on risk assessment for inherited gynecologic cancer predispositions. / SGO Clinical Practice Committee.

In: Gynecologic Oncology, Vol. 136, No. 1, 2015, p. 3-7.

Research output: Contribution to journalArticle

@article{ba428ea2afd64da2a8ba7c0cf307c8ca,
title = "Society of gynecologic oncology statement on risk assessment for inherited gynecologic cancer predispositions",
abstract = "Women with germline mutations in the cancer susceptibility genes, BRCA1 or BRCA2, associated with Hereditary Breast & Ovarian Cancer syndrome, have up to an 85{\%} lifetime risk of breast cancer and up to a 46{\%} lifetime risk of ovarian, tubal, and peritoneal cancers. Similarly, women with mutations in the DNA mismatch repair genes, MLH1, MSH2, MSH6, or PMS2, associated with the Lynch/Hereditary Non-Polyposis Colorectal Cancer (HNPCC) syndrome, have up to a 40-60{\%} lifetime risk of both endometrial and colorectal cancers as well as a 9-12{\%} lifetime risk of ovarian cancer. Mutations in other genes including TP53, PTEN, and STK11 are responsible for hereditary syndromes associated with gynecologic, breast, and other cancers. Evaluation of the likelihood of a patient having one of these gynecologic cancer predisposition syndromes enables physicians to provide individualized assessments of cancer risk, as well as the opportunity to provide tailored screening and prevention strategies such as surveillance, chemoprevention, and prophylactic surgery that may reduce the morbidity and mortality associated with these syndromes. Evaluation for the presence of a hereditary cancer syndrome is a process that includes assessment of clinical and tumor characteristics, education and counseling conducted by a provider with expertise in cancer genetics, and may include genetic testing after appropriate consent is obtained. This commentary provides guidance on identification of patients who may benefit from assessment for the presence of a hereditary breast and/or gynecologic cancer syndrome.",
keywords = "BRCA1, BRCA2, Cowden syndrome, Genetic testing, Hereditary cancer, Lynch syndrome",
author = "{SGO Clinical Practice Committee} and Lancaster, {Johnathan M.} and Powell, {C. Bethan} and Chen, {Lee May} and Richardson, {Debra L.}",
year = "2015",
doi = "10.1016/j.ygyno.2014.09.009",
language = "English (US)",
volume = "136",
pages = "3--7",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Society of gynecologic oncology statement on risk assessment for inherited gynecologic cancer predispositions

AU - SGO Clinical Practice Committee

AU - Lancaster, Johnathan M.

AU - Powell, C. Bethan

AU - Chen, Lee May

AU - Richardson, Debra L.

PY - 2015

Y1 - 2015

N2 - Women with germline mutations in the cancer susceptibility genes, BRCA1 or BRCA2, associated with Hereditary Breast & Ovarian Cancer syndrome, have up to an 85% lifetime risk of breast cancer and up to a 46% lifetime risk of ovarian, tubal, and peritoneal cancers. Similarly, women with mutations in the DNA mismatch repair genes, MLH1, MSH2, MSH6, or PMS2, associated with the Lynch/Hereditary Non-Polyposis Colorectal Cancer (HNPCC) syndrome, have up to a 40-60% lifetime risk of both endometrial and colorectal cancers as well as a 9-12% lifetime risk of ovarian cancer. Mutations in other genes including TP53, PTEN, and STK11 are responsible for hereditary syndromes associated with gynecologic, breast, and other cancers. Evaluation of the likelihood of a patient having one of these gynecologic cancer predisposition syndromes enables physicians to provide individualized assessments of cancer risk, as well as the opportunity to provide tailored screening and prevention strategies such as surveillance, chemoprevention, and prophylactic surgery that may reduce the morbidity and mortality associated with these syndromes. Evaluation for the presence of a hereditary cancer syndrome is a process that includes assessment of clinical and tumor characteristics, education and counseling conducted by a provider with expertise in cancer genetics, and may include genetic testing after appropriate consent is obtained. This commentary provides guidance on identification of patients who may benefit from assessment for the presence of a hereditary breast and/or gynecologic cancer syndrome.

AB - Women with germline mutations in the cancer susceptibility genes, BRCA1 or BRCA2, associated with Hereditary Breast & Ovarian Cancer syndrome, have up to an 85% lifetime risk of breast cancer and up to a 46% lifetime risk of ovarian, tubal, and peritoneal cancers. Similarly, women with mutations in the DNA mismatch repair genes, MLH1, MSH2, MSH6, or PMS2, associated with the Lynch/Hereditary Non-Polyposis Colorectal Cancer (HNPCC) syndrome, have up to a 40-60% lifetime risk of both endometrial and colorectal cancers as well as a 9-12% lifetime risk of ovarian cancer. Mutations in other genes including TP53, PTEN, and STK11 are responsible for hereditary syndromes associated with gynecologic, breast, and other cancers. Evaluation of the likelihood of a patient having one of these gynecologic cancer predisposition syndromes enables physicians to provide individualized assessments of cancer risk, as well as the opportunity to provide tailored screening and prevention strategies such as surveillance, chemoprevention, and prophylactic surgery that may reduce the morbidity and mortality associated with these syndromes. Evaluation for the presence of a hereditary cancer syndrome is a process that includes assessment of clinical and tumor characteristics, education and counseling conducted by a provider with expertise in cancer genetics, and may include genetic testing after appropriate consent is obtained. This commentary provides guidance on identification of patients who may benefit from assessment for the presence of a hereditary breast and/or gynecologic cancer syndrome.

KW - BRCA1

KW - BRCA2

KW - Cowden syndrome

KW - Genetic testing

KW - Hereditary cancer

KW - Lynch syndrome

UR - http://www.scopus.com/inward/record.url?scp=84925229366&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925229366&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2014.09.009

DO - 10.1016/j.ygyno.2014.09.009

M3 - Article

C2 - 25238946

AN - SCOPUS:84925229366

VL - 136

SP - 3

EP - 7

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -